ADAGENE INC-ADR (ADAG)
US0053291078 - ADR
Taking everything into account, ADAG scores 2 out of 10 in our fundamental rating. ADAG was compared to 588 industry peers in the Biotechnology industry. ADAG has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ADAG is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
ADAG had negative earnings in the past year.
ADAG had a negative operating cash flow in the past year.
In the past 5 years ADAG always reported negative net income.
ADAG had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ADAG has a better Return On Assets (-16.37%) than 86.18% of its industry peers.
ADAG has a better Return On Equity (-26.85%) than 82.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.37% | ||
| ROE | -26.85% | ||
| ROIC | N/A |
ROA(3y)-35.83%
ROA(5y)-34.76%
ROE(3y)-56.61%
ROE(5y)-50.5%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ADAG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ADAG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADAG has more shares outstanding
Compared to 5 years ago, ADAG has more shares outstanding
Compared to 1 year ago, ADAG has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.63, we must say that ADAG is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ADAG (-1.63) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.25 indicates that ADAG is not too dependend on debt financing.
The Debt to Equity ratio of ADAG (0.25) is worse than 69.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.63 |
ROIC/WACCN/A
WACC6.74%
2.3 Liquidity
A Current Ratio of 3.61 indicates that ADAG has no problem at all paying its short term obligations.
ADAG has a Current ratio (3.61) which is in line with its industry peers.
A Quick Ratio of 3.61 indicates that ADAG has no problem at all paying its short term obligations.
ADAG has a Quick ratio (3.61) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.61 | ||
| Quick Ratio | 3.61 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 76.61% over the past year.
Looking at the last year, ADAG shows a very strong growth in Revenue. The Revenue has grown by 94.96%.
Measured over the past years, ADAG shows a very strong growth in Revenue. The Revenue has been growing by 64.36% on average per year.
EPS 1Y (TTM)76.61%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q55.05%
Revenue 1Y (TTM)94.96%
Revenue growth 3Y195.77%
Revenue growth 5Y64.36%
Revenue growth Q2Q-84.81%
3.2 Future
Based on estimates for the next years, ADAG will show a small growth in Earnings Per Share. The EPS will grow by 7.29% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y17.47%
EPS Next 2Y5.71%
EPS Next 3Y7.29%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ADAG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADAG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.71%
EPS Next 3Y7.29%
5. Dividend
5.1 Amount
No dividends for ADAG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADAGENE INC-ADR
NASDAQ:ADAG (4/29/2024, 1:03:36 PM)
2.27
-0.12 (-5.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap100.24M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.37% | ||
| ROE | -26.85% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.61 | ||
| Quick Ratio | 3.61 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)76.61%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y17.47%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)94.96%
Revenue growth 3Y195.77%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y